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Production of anti-breast cancer monoclonal antibodies using a
glutathione-S-transferase-MUC1 bacterial fusion protein
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Summary Two murine Mabs VAl(IgGl) and VA2(IgGl) were produced against a bacterial fusion protein
comprising glutathione S-transferase and five tandem repeats of the MUC1 protein. Using the immunoperoxi-
dase staining technique, VAI detected 46/53 and VA2 detected 48/53 breast cancers and both also reacted with
a range of other human epithelial carcinomas. In addition VAI gave weak reactions with normal breast tissues
whereas VA2 was non-reactive and could be a relatively tumour specific antibody for breast cancer. The
antibodies were also tested by ELISA-VAI reacted weakly with glycosylated HMFG but strongly with
deglycosylated HMFG, whereas VA2 reacted strongly with both forms of HMFG. The reactivities of the two
Mabs with synthetic peptides of the MUCI tandem repeat were used to map the epitopes recognised by VAI
(amino acids RPAPGS) and VA2 (amino acids DTRPA). The use of fusion proteins provides another means
of immunisation to produce anti-tumour antibodies.
Mucins are heavily glycosylated glycoproteins (>200 Kd)
which are produced by many epithelial cells and tumours
(Gendler et al., 1988). Mucins found on cancer cells are
different in some respects to those present on normal
epithelial cells, in that some mucins have a deficiency in their
carbohydrate coat which leaves the protein core exposed
(Harisch et al., 1989). Monoclonal antibodies (Mabs) reac-
ting with the mucin core proteins may therefore show a
different reactivity with normal and malignant tissues. This
raises the possibility that some epitopes ofmucins may act as
markers for the malignant state and/or as targets against
which therapeutic Mabs could be directed. The cDNA
sequence of the protein core of the mammary mucin, MUCI,
has been cloned and found to consist of unique amino and
carboxyl sequences separated by a highly repetitive central
portion containing 40-80 tandemly arranged copies of a 20
amino acid motif (APDTRPAPGSTAPPAHGVTS) (Mar-
jolijn et al., 1990). As the number of repeats expressed by
any individual is polymorphic, this region is referred to as
VNTR (variable number tandem repeats), but there is no
association between the number of repeats and susceptibility
to malignancy (Crocker & Price, 1987). Mabs have been
raised against naturally occurring mucin in human milk fat
globule protein (HMFG) and against synthetic peptides
representing portions of the repetitive region (Xing et al.,
1989) and some of these antibodies have been found to be
useful markers of progression of malignant disease and in
imaging tumour deposits (Xing et al., 1989). The iden-
tification of cancer-associated peptide epitopes on mucins has
been hampered by the nature of the immunising material.
The protein core of naturally occurring mucin (HMFG) can
be masked by different groups of carbohydrates unless
chemically stripped of carbohydrate side chains prior to
immunisation. Alternatively, the use of synthetic peptides for
immunisation has the disadvantage that protein folding to
produce accurate secondary and tertiary structures is unlikely
to occur as the peptides are too short (Xing et al., 1992). One
means of overcoming these problems is to express a number
of the repetitive units in a bacterial expression system, as this
would provide non-glycosylated polypeptide of sufficient
length to fold in a manner similar to the natural mucin.
Using this approach, we now report two Mabs which recog-
nise peptide epitopes on breast cancer mucin. One such Mab,
VA1, reacted with breast cancer and normal tissue, whereas a
second Mab VA2, showed a high degree of specificity for
breast cancer tissue.
Materials and methods
Production ofsoluble GST-MUCJ fusion protein
A 309 base pair insert (PDF9.3) encoding a little more than
five repeats of a 60 base pair motiffrom the VNTR region of
MUC1 cDNA (Siddiqui et al., 1988) was subcloned into the
bacterial expression vector pGEX-3X, in the correct reading
frame and orientation (Smith & Johnson, 1988). Fusion pro-
tein, consisting of glutathione-S-transferase (GST) and
MUCI VNTR, was induced with 0.1 mM IPTG (Smith &
Johnson, 1988). Cells were collected by centrifugation,
washed and lysed by sonication in buffer containing 1% (v/v)
Triton X-100. Supernatant containing the soluble fusion pro-
tein was mixed with glutathione-agarose beads (sulphur-
linked) (Sigma, St. Louis, USA) and collected by centrifuga-
tion. The fusion protein was eluted with buffer containing
5 mM reduced glutathione, dialysed against phosphate
buffered saline and analysed by SDS-PAGE.
Preparation ofpeptides and HMFG
Peptides (Table I) were synthesised using an Applied Bio-
systems Model 430A automated peptide synthesiser (Hodges
& Merrifield, 1975; Kent & Hood, 1984). HMFG and deg-
lycosylated HMFG were prepared as previously described
(Xing et al., 1989).
Immunisation andproduction ofMabs
(CBA x BALB/c)FI mice (females aged 8 weeks) were
immunised intraperitoneally with 50jig of the fusion protein
emulsified with complete Freund's adjuvant and this was
repeated four and six weeks later. Three days prior to cell
fusion a boost of soluble fusion protein was given intra-
venously and a cell fusion performed (Thompson et al.,
1983). Hybridomas were selected on the basis of a strong
reaction of the supernatant of the immunogen, and a
negative reaction with an irrelevant synthetic peptide (T4N1)
and GST. The immunoglobulin isotype of the Mabs was
determined by Ouchterlony gel immunodiffusion using rabbit
antisera to mouse immunoglobulins (Serotec, Oxford, Eng-
land). The hybridomas were grown as ascites tumours in
pristane-primed (CBA x BALB/c)FI mice and the Mabs
(IgGI subclass) were purified from the mouse ascites fluid
using a Protein A-Sepharose 4B column.
Immunoperoxidase staining andELISA assays
The immunoperoxidase staining on tissue sections was per-
formed (Stacker et al., 1985) and the reactions graded ac-
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Table I Reaction of monoclonal antibodies with synthetic peptides tested by solid phase
ELISA
Optical density
Peptide amino acid composition (No.) VAI VA2
VNTR-GST (PDTRPAPGSTAPPAHGVTSA) x 5-GST (103) 2.00 1.90
P1-24 PDTRPAPGSTAPPAHGVTSAPDTR (24) 0.48 0.11
P1-15 PDTRPAPGSTAPPAH (15) 0.28 0.09
P5-20 PAPGSTAPPAHGVTSA (16) 0.08 0.08
P13-32 PAHGVTSAPDTRPAPGSTAP (20) 0.12 0.05
C-P13-32 C-PAHGVTSAPDTRPAPGSTAP (21) 1.99 1.83
T4N1 KTLVLGLEQESAELPCEY (19) 0.11 0.13
HMFG 0.39 0.90
D.HMFG 1.26 1.25
GST 0.22 0.17
Optical Density values taken at one-tenth dilution of tissue culture supernatant of
hybridomas. HMFG = Human milk fat globule membrane. D.HMFG = deglycosylated
HMFG.
cording to the percentage of cells stained: 0% (-), <25%
(1+), 25-50% (2+), 50-75% (3 + ),>75% (4+) and the
intensity of staining: negative (-), weak (1 + ), moderate
(2 + ), strong (3 + ), very strong (4 + ). The solid phase and
the inhibition (liquid phase) ELISA tests were performed as
described (Xing et al., 1989; Xing et al., 1991). For the direct
test, 20 igmlml of peptides and 10ligmlm' of HMFG and
deglycosylated HMFG were coated in the wells of a mic-
rotitre plate. Non specific binding was blocked and the
antibody reacted for 2 h. For the inhibition studies C-p13-32
pre-coated plates (20 pg ml-1) were used to test the peptides,
which at increasing concentrations (3.6 x 10-5-0.08 mM)
were mixed with the antibodies and left on the plates for 2 h.
Epitope mapping using the pepscan method
Peptides corresponding to the MUC1 sequence were syn-
thesised on polyethylene pins and consisted of twenty over-
lapping 6-mer peptides e.g. PDTRPA, DTRPAP, TRPAPG
APDTRP. The Mabs were tested for binding to the
peptides on pins using the ELISA method (Xing et al., 1991).
Results
Production ofMabs detecting a GST-MUCIfusion protein
A bacterial fusion protein consisting of GST (26 Kd) and five
repeats of the MUC1 VNTR 20-mer peptide was induced in
E. coli, purified and used to raise Mabs. Hybridomas were
selected on the basis of reactivity with the MUC1 fusion
protein, lack of reactivity with an irrelevant synthetic peptide
(T4NI) and GST (Table I), and a reaction on formalin fixed
breast cancer tissues detected by the immunoperoxidase tech-
nique. Two hybridomas, VA1 and VA2 were selected for
further study on the basis of the selection criteria.
Reaction ofMabs with synthetic peptides, HMFG and the
fusion protein
Each antibody was tested on natural and deglycosylated
HMFG, the fusion protein and on a number of peptides
whose sequence was based on that of the MUC1 VNTR
sequence (Table I). In addition to the immunising fusion
protein (VNTR-GST), VAI reacted strongly with C-pl3-32
(a dimeric form of p13-32, composed of disulphide linked
monomers) and with deglycosylated HMFG but weakly with
the p13-32 monomer peptide and with the fully glycosylated
HMFG. The reactivity with the dimer peptide (C-pl3-32) but
not with p13-32 or other monomeric peptides (Table I) was
of interest and indicated that the antibodies may be more
reactive when a secondary structure is allowed to form. We
found however that small peptides synthesised on pins were
reactive (see below). To further study the reactions, the pep-
tides were used in inhibition studies (Figure la, b) and the
differences noted in direct studies were not observed. For
these studies, peptides in solution were used to inhibit the
reaction of VAI (Figure la) with C-p13-32 on the plate. The
peptides C-pl3-32, p13-32, pl-15, pl-24 and p5-20 all
inhibited; in particular, C-p13-32 and p13-32 on a molar
basis, gave similar inhibition. HMFG also gave some inhibi-
tion, although virtually no reaction was noted when HMFG
was coated on the plate (Table I). The reactions ofVA2 were
similar to VAI but with some notable differences. In addition
to the immunisating fusion protein, VA2 reacted with both
forms of HMFG. The peptides C-pl3-32, p13-32, pl-15, and
pl-24 all inhibited in the inhibition assay (Figure lb)
although in the solid phase ELISA only C-p13-32 was reac-
tive (Table I).
Reaction ofMabs with human tissue
The reactivities of the two antibodies VAI and VA2 with
various tumours are shown in Table II and Table IV. Using
the immunoperoxidase staining technique Mab VAI reacted
with 46/53 (87%) breast cancers and VA2 with 48/53 (91%)
(Figure 2). VAI and VA2 were clearly not breast cancer
specific as they reacted with other cancers (Tables II and IV).
VAl gave weak reactions with formalin fixed normal breast
epithelial cells in acini and ducts, but a stronger reaction on
fresh breast tissues (Figure 3a), whereas VA2 showed no such
reaction on all formalin fixed tissues and a weak reaction
with fresh normal breasts (Figure 3b). Both Mabs gave addi-
tional weak reactions (luminal, cell surface, secretion, cyto-
plasmic) with other normal tissues (Table III and Table V).
Both VAl and VA2 reacted strongly with normal colon
tissues (all cells within the gland were positive). MUC1 pro-
tein is not thought to be expressed by normal colon but we
note that normal colon does indeed express MUC1 (Figure
4). Likewise with normal ovary both antibodies reacted with
formalin fixed tissues. In general, the staining was weaker on
normal tissues than on cancer tissues and stronger on fresh
tissue than on formalin fixed tissue. Comparing the two
Mabs with Mab BC2 (an anti-MUCI antibody produced
using whole mucin HMFG as the immunogen and which
reacted with the amino acids APDTR) some differences were
noted. The staining intensity of BC2 on both normal kidney
and carcinoma of the kidney was intense, in contrast to VAl
and VA2 where much weaker reactions were observed. In
addition the staining intensity of VAl and VA2 in some
breast carcinomas was more intense than that of BC2. Also
the staining pattern of BC2 on colon carcinoma (formalin
fixed) was different to that of VA1 and VA2 as BC2 showed
a luminal staining pattern and stained the secretions, whereas
VA1 and VA2 showed only a weak cytoplasmic staining only
(data not shown). Thus, the staining properties of the anti-ANTI-GST-MUC1 FUSION PROTEIN MABS 715
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Figure 1 Inhibition assay of the binding of Mab (a) VAI and (b) VA2 to C-p13-32 using synthetic peptides at increasing
concentrations (3.6 x 10-5-0.08 mM).
Table II Reaction of Mabs VAI and VA2 with formalin fixed human tumours by immunoperoxidase staining
VA] VA2
No. of +ve % of cancer No. of +ve % of cancer
Tumour stainingl cells staining stainingl cells staining
tissue total tested staininga intensity" total tested staining intensity
+ 2+ 3+ 4+ + 2+ 3+ 4+ + 2+ 3+ 4+ + 2+ 3+ 4+
Breast (Br.) 46/53 17 8 10 11 5 14 14 13 48/53 23 7 5 12 11 11 10 16
Ovary 3/5 1 0 0 2 1 1 0 1 2/5 0 0 1 1 1 1 0 0
Pancreas 2/2 0 1 1 0 0 0 1 1 2/2 0 1 0 1 0 0 2 0
Kidney 8/12 3 3 2 0 4 1 1 2 7/12 3 2 1 1 1 2 2 2
Prostate 1/2 0 1 0 0 0 1 0 0 2/2 2 0 0 0 1 1 0 0
Stomach 5/5 2 0 1 2 0 3 0 2 5/5 2 0 1 2 1 2 0 2
Liver 1/1 0 1 0 0 0 0 1 0 1/1 1 0 0 0 0 0 1 0
Lung 7/12 3 4 0 0 1 4 2 0 6/12 3 2 1 0 0 5 0 1
Colon 9/22 6 2 1 0 3 3 2 1 5/22 4 1 0 0 1 3 1 0
Br. fibroadenoma 3/6 1 0 1 1 0 2 1 0 3/6 2 1 0 0 1 2 0 0
Br. Cystic hyperplasia 0/4 0 0 0 0 0 0 0 0 0/4 0 0 0 0 0 0 0 0
aStaining was graded: 0% (-); <25% (+); 25-50% (2+); 50-75% (3+); >75% (4+); bStaining intensity was graded: negative (-);
moderate (2+); strong (3+); very strong (4+); The gradings of a and b were performed by two individuals.
Table III Reaction of Mabs VAI and VA2 with formalin fixed normal tissue by immunoperoxidase staining
VA] VA2
No. of +ve % of normal No. of +ve % of normal
staining/ cells staining staining/ cells staining
Tissue total tested staining' intensity" total tested staining intensity
+ 2+ 3+ 4+ + 2+ 3+ 4+ + 2+ 3+ 4+ + 2+ 3+ 4+
Breast 5/10 3 2 0 0 1 4 0 0 0/10 0 0 0 0 0 0 0 0
Colon 6/13 2 1 1 2 2 1 2 1 4/13 1 2 0 1 2 1 1 0
Ovary 2/2 1 0 1 0 0 2 0 0 2/2 1 0 1 0 0 2 0 0
Salivary gland 2/2 0 0 2 0 0 0 2 0 2/2 0 0 2 0 0 1 1 0
Pancreas 2/2 0 0 0 2 0 0 0 2 2/2 0 0 0 2 0 0 0 2
Small intestine 1/1 0 1 0 0 0 1 0 0 1/1 1 0 0 0 1 0 0 0
Cervix 0/1 0 0 0 0 0 0 0 0 0/1 0 0 0 0 0 0 0 0
Gall bladder 1/4 1 0 0 0 1 0 0 0 0/4 0 0 0 0 0 0 0 0
Stomach 2/2 0 0 1 1 0 0 1 1 2/2 0 0 1 1 0 0 1 1
Liver 0/1 0 0 0 0 0 0 0 0 0/1 0 0 0 0 0 0 0 0
Lung 3/6 0 3 0 0 1 2 0 0 5/6 2 3 0 0 2 3 0 0
Kidney 3/4 2 0 1 0 0 2 1 0 3/4 1 1 1 0 1 0 2 0
aStaining was graded: 0% (-); <25% (+); 25-50% (2+); 50-75% (3+); >75% (4+); bStaining intensity was graded: negative (-); weak
(+) moderate (2+); strong (3+); very strong (4+); The gradings of a and b were performed by two individuals.
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Figure 2 Immunoperoxidase staining of infiltrating duct breast carcinoma tissue with antibody VA2 showing intense cell surface
and cytoplasmic staining (original manification x 20). VAI showed similar staining.
Table IV Reaction of Mabs VAI and VA2 with fresh human tumour tissues by immunoperoxidase staining
VA] VA2
No. of +ve % of cancer No. of +ve % of cancer
Tumour stainingl cells staining stainingl cells staining
tissue total tested staining' intensityb total tested staining intensity
+ 2+ 3+ 4+ + 2+ 3+ 4+ + 2+ 3+ 4+ + 2+ 3+ 4+
Breast 5/5 0 2 0 3 0 1 3 1 5/5 0 2 0 3 0 2 2 1
Ovary 1/1 0 0 1 0 0 0 1 0 1/1 0 0 0 1 0 1 0 0
Stomach 3/3 0 1 0 2 0 0 1 2 3/3 0 1 0 2 0 0 1 2
Colon 4/5 1 2 1 0 0 2 1 1 4/5 2 1 1 0 2 0 1 1
Lung 10/10 3 2 2 3 2 3 3 2 10/10 4 2 1 3 3 3 2 2
aStaining was graded: 0% (-); <25% (+); 25-50% (2+); 50-75% (3+); >75% (4+); bStaining intensity was graded: negative (-); weak
(+) moderate (2+); strong (3+); very strong (4+); The gradings of a and b were performed by two individuals.
fusion protein antibodies VAl and VA2 differ substantially
from those of BC2.
Epitopes detectedby VAI and VA2
To define the precise epitopes detected by VAI and VA2, the
'pepscan' method was used. In this method overlapping pep-
tides were examined and the peptide RPAPGS showed a
strong reaction with VA1 and the peptides TRPAPG,
PAPGST and APGSTA gave a weaker reaction. APG is
common and is a partial epitope whereas RPAPGS the full
epitope (Figure 5a). For VA2 the two peptides DTRPAP and
PDTRPA showed strong reactivity and the common amino
acids in the epitope are DTRPA (Figure Sb).ANTI-GST-MUCI FUSION PROTEIN MABS 717
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Figure 3 Immunoperoxidase staining of normal breast tissue with (a) antibody VAI and (b) antibody VA2 showing the amount of
staining (original magnification x 20).
Table V Reaction of Mabs VA1 and VA2 with normal fresh tissues by immunoperoxidase staining
VA] VA2
No. of +ve % of normal No. of +ve % of normal
stainingl cells staining stainingl cells staining
Tissue total tested staininge intensityk total tested staining intensity
+ 2+ 3+ 4+ + 2+ 3+ 4+ + 2+ 3+ 4+ + 2+ 3+ 4+
Breast 3/3 0 0 1 2 0 0 1 2 2/3 2 0 0 0 1 1 0 0
Trachea 1/2 0 1 0 0 0 1 0 0 1/2 0 1 0 0 0 1 0 0
Lung 5/5 0 1 3 1 1 2 1 1 5/5 0 3 1 1 1 3 0 1
Salivary gland 1/1 0 0 0 1 0 0 0 1 1/1 0 0 1 0 0 0 1 0
Stomach 4/5 0 1 0 3 0 1 2 1 4/5 1 0 2 1 1 2 0 1
Small intestine 3/3 0 1 1 1 0 2 0 1 3/3 0 1 1 1 1 1 1 0
Colon 8/8 0 0 1 7 0 0 0 8 8/8 0 1 1 6 0 0 5 3
Rectum 4/4 0 0 2 2 0 1 1 2 4/4 0 2 0 2 0 2 1 1
Pancreas 3/3 0 0 2 1 0 1 2 1 3/3 0 0 2 1 0 0 1 2
Appendix 0/1 0 0 0 0 0 0 0 0 0/1 0 0 0 0 0 0 0 0
Spleen 1/1 0 0 0 1 0 0 0 1 1/1 0 0 0 1 0 0 0 1
Kidney 3/3 0 0 3 0 0 1 2 0 3/3 0 1 2 0 0 0 2 1
Liver 0/2 0 0 0 0 0 0 0 0 0/2 0 0 0 0 0 0 0 0
Bladder 0/3 0 0 0 0 0 0 0 0 0/3 0 0 0 0 0 0 0 0
Gall bladder 0/3 0 0 0 0 0 0 0 0 0/3 0 0 0 0 0 0 0 0
Ovary 0/1 0 0 0 0 0 0 0 0 0/1 0 0 0 0 0 0 0 0
Uterus 0/1 0 0 0 0 0 0 0 0 0/1 0 0 0 0 0 0 0 0
aStaining was graded: 0% (-); <25% (+); 25-50% (2+); 50-75% (3+); > 75% (4+); bStaining intensity was graded: negative (-); weak
(+) moderate (2+); strong (3+); very strong (4+); The gradings of a and b were performed by two individuals.718 V. APOSTOLOPOULOS et al.
Figure 4 Immunoperoxidase staining of colon carcinoma tissue stained with antibody VAl showing intense glandular staining
(original magnification x 20). VA2 showed similar staining.
Discussion
This report describes the production of Mabs VAI and VA2
against a MUCI bacterial fusion protein. A fusion protein
derived from the MUCI cDNA clone which contained five
VNTR's of 100 amino acids in length (which is too long to
be realistically produced as a synthetic peptide) was produced
in E. coli, affinity purified and used to generate two Mabs,
VAI and VA2. These antibodies have unique characteristics
when compared to Mabs made to natural mucin (BC2).
Antibody VAI reacted with most breast carcinoma tissues
and showed a weak reaction with normal breast tissues. It
also reacted with a variety of other epithelial tissues, both
cancer and normal tissue. By contrast Mab VA2 reacted with
breast carcinomas but was non-reactive on all ten formalin
fixed normal breast tissues and a weak reaction with fresh
breast tissues. This clear differentiation between normal and
malignant breast tissues makes both antibodies potentially
good candidates for clinical uses, particularly VA2. Compar-
ing Mabs VAI and VA2 with the anti-mucin Mab BC2,
different staining patterns were noted, even though BC2 also
reacts with MUCI, but with a different peptide (APDTR).
Mab NCRC-l1 (Price et al., 1990) recognises the epitope
RPA. This epitope is in the hydrophilic turn region of the
peptide and suggests that the peptide core is exterior of the
glycoprotein where the antibody binds. The amino acids
PDTRPAP are exposed in cancer mucins, and indeed VAI
and VA2 have reactive epitopes within this region. It was
also shown that in the 20 amino acid repeat there is no
potential for P sheet or a helix formation (Price et al., 1990).
High field NMR studies were taken from 11 amino acid
fragment of the sequence, and revealing elements of secon-
dary structure to be present (Tendler et al., 1990). A type 1 p
turn from D(2)-R(4) was found which extends by P(3) being
in the trans form. The turn region extends into the epitopes
known for Mabs such as C595 and NCR-Il (Price et al.,
1990) as well as VAl and VA2.
VAI and VA2 gave differential reactions on tissue sections,
HMFG, deglycosylated HMFG and on peptides. Firstly VAI
reacted with both cancer and normal tissues, not with
HMFG but with deglycosylated HMFG and with the peptide
epitope RPAPGS. The pattern of reactivity of VAI fits what
is now considered to occur with MUCI expression in normal
and malignant tissue. It has been proposed, largely on theANTI-GST-MUC1 FUSION PROTEIN MABS 719
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Figure 5 Reactivity of 1/10 dilution of tissue culture supernatant of (a) VAI and (b) VA2 with synthetic peptides synthesised on
pins.
basis of the reactivity of the SM3 antibody (made to degly-
cosylated HMFG) (Burchell et al., 1987) that there is altered
or defective glycosylation in malignancy, so antibodies to
MUCI core proteins react weakly with normal tissue and
HMFG, but more strongly on deglycosylated HMFG and
cancer cells, i.e. VAI pattern. The reactivity of VA2 is similar
other than for the stronger reaction on whole HMFG. The
reason for this is not clear, possibly the DTRPA epitope is
exposed in HMFG than the epitope RPAPGS; it is possible
that threonine (T) in DTRPA is not glycosylated, clearly
making this epitope more accessible. Other DTR reactive
Abs are SM3 and HMFG (Burchell et al., 1989) and SM3 in
particular does not react with HMFG but does so with
deglycosylated HMFG.
Both antibodies showed no reaction with synthetic peptides
pl-15, pl-24, and p13-32 in a solid phase ELISA (Table I)
even though they contain the epitope recognised by the
antibodies. However both antibodies could react with the
peptides in liquid phase (in the inhibition studies). It is likely
that the peptides in a solid phase lose conformation as they
attach to the plate, and the antibodies are unable to see their
corresponding determinants. Thus, although the predominant
reaction is with the primary sequence of the peptide, some
conformational alteration occurs in solution or when the
peptide is attached at one end, as with the pins, permitting
stronger reaction with the antibody.
Fusion proteins have recently been used to test antibodies,
e.g. MUCI for HMFG-1 and HMFG-2 and for anti-CEA
antibodies to map the domain reactivity (Burchell et al.,
1987; Hass et al., 1991). We now show that fusion proteins
can also be used to produce antibodies. Are these of any
advantage over HMFG, tumour extracts or synthetic peptide
- it remains to be seen in various diagnostic and therapeutic
tests. However the differential reactivity on HMFG and deg-
lycosylated HMFG, on C-pl3-32 vs p13-32 and on tumour
and normal tissues (i.e. VA2) indicate that these antibodies
may be the most specific made thus far. The Mab SM3
(Burchell et al., 1987) which recognises an epitope exposed in
the mucin as processed by the tumour cells and not exposed
on normal mucin, gave weak reactions with normal breast
and other normal tissues. VA2 reacted with normal tissues
and reacted weakly with only fresh normal breast, indicating
that it may be a useful diagnostic or therapeutic agent for
breast cancer.
We would like to thank Dr G.A. Pietersz for helpful discussions.
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